No data to show
XNAS
HOOK
Market cap10mUSD
Apr 25, Last price
0.80USD
1D
1.18%
1Q
-60.83%
IPO
-93.93%
Name
HOOKIPA Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-6.83%
Rev. gr., 5y
21.41%
Revenues
0k
-100.00%
Net income
-44m
L-46.67%
CFO
-77m
L+33.82%
Earnings
May 07, 2025
Profile
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | 20,129 41.27% | 14,249 -22.76% | ||||||
Cost of revenue | 88,733 | 108,609 | 91,006 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (88,733) | (88,480) | (76,757) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 106 | 368 | 230 | |||||
Tax Rate | ||||||||
NOPAT | (88,839) | (88,848) | (76,987) | |||||
Net income | (43,503) -46.67% | (81,580) 25.67% | (64,915) -14.21% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 49,043 | 75,121 | ||||||
BB yield | -640.53% | -1,414.38% | ||||||
| Debt | ||||||||
Debt current | 552 | 4,396 | 3,282 | |||||
Long-term debt | 1,198 | 9,240 | 7,219 | |||||
Deferred revenue | 19,674 | 25,664 | ||||||
Other long-term liabilities | 6,355 | 6,017 | 3,420 | |||||
Net debt | (37,934) | (103,460) | (103,362) | |||||
| Cash flow | ||||||||
Cash from operating activities | (76,978) | (57,524) | (19,997) | |||||
CAPEX | (4,159) | (5,017) | ||||||
Cash from investing activities | (194) | (4,159) | (5,017) | |||||
Cash from financing activities | (1,276) | 65,670 | 72,271 | |||||
FCF | (93,568) | (78,685) | (66,186) | |||||
| Balance | ||||||||
Cash | 39,684 | 117,096 | 113,444 | |||||
Long term investments | 419 | |||||||
Excess cash | 39,684 | 116,090 | 113,151 | |||||
Stockholders' equity | (417,850) | (377,184) | (294,832) | |||||
Invested Capital | 476,294 | 496,550 | 432,706 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 12,539 | 9,453 | 6,557 | |||||
Price | 2.01 148.15% | 0.81 0.00% | 0.81 -65.24% | |||||
Market cap | 25,203 229.16% | 7,657 44.16% | 5,311 -30.71% | |||||
EV | (12,731) | (95,803) | (98,051) | |||||
EBITDA | (88,733) | (84,928) | (73,155) | |||||
EV/EBITDA | 0.14 | 1.13 | 1.34 | |||||
Interest | 2 | 317 | 687 | |||||
Interest/NOPBT | ||||||||